A double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg FTY720 administered orally once daily Versus Placebo in Patients with Primary Progressive Multiple Sclerosis

UVA Health System, Department of Neurology, seeks men and Women ages 25 through 65 with Primary Progressive Multiple Sclerosis for research study.

The purpose of the study is to evaluate whether an oral experimental drug, FTY720, helps delay MS disability progression in persons who are not experiencing relapses, compared to placebo. Potentially eligible people should have symptoms which started between 2 and 10 years ago, and must be able to walk on their own or with a cane at least 100 meters. Study involves taking an experimental medicine/placebo, blood draws, MRIs, chest CT, chest x-ray, pulmonary function testing, eye exams, dermatology exams, physical and neurological exams and completion of surveys. There are at least 20 visits over at least 3 ½ years. Visits last between 1 and 8 hours.

Study-related medication and examinations are provided free of charge.

Compensation:

Participants are compensated $50 for each completed study visit